July 2016

Studies of interest

Are you depressed and have worries or thoughts that don’t make sense? (Docket # H-14207)

Patients that are currently suffering from depression with irrational worries are invited to participate in a research study to determine how long people need to stay on an antipsychotic medication after they recover from their symptoms. Study participation will last up to 20 weeks and patients will receive a combination of an antipsychotic medication and an antidepressant medication. Patients must be: 18 to 85 years of age, experiencing symptoms of depression with irrational worries, and not be pregnant. Patients will receive study medication and study-related care at no cost. Qualifying patients will be eligible to participate in 9-month follow-up study. Compensation provided. Contact Chelsea Kosma @ 508-856-5312.

Sexual Dysfunction in patients with Parkinson’s disease (Docket # H00009669)

Neurologists specialized in Movement Disorders at UMass Medical School are studying the effect of Parkinson's Disease on sexual dysfunction in women. Participants will complete an anonymous questionnaire. For more information, please contact Anas Hannoun, MD at 508-334-2527 or Anas.Hannoun@umassmemorial.org.

Advanced Imaging to Quantify Joint Deformity in Rheumatic Disease (Docket # H00008930)

The purpose of this study is to collect one blood sample and to perform high resolution CT scans of the hands of rheumatoid arthritis patients, psoriatic arthritis patients and healthy controls. The information from this study will help researchers develop better tools to predict disease progression and disability in rheumatoid arthritis and psoriatic arthritis. The long term goal of this study is to improve the treatment of arthritis and the quality of life of patients with both conditions. For more information, please contact Janice Weaver at Janice.Weaver@umassmed.edu.

Do you have Rheumatoid Arthritis? (Docket # H00004371)

The study will monitor the safety and effectiveness of tofacitinib (Xeljanz) and a tumor necrosis factor inhibitor (TNFi), adalimumab (Humira) in subjects with rheumatoid arthritis, comparing the incidence of cardiovascular events and malignancies. Inclusion Criteria: • Moderate to severe rheumatoid arthritis • Taking methotrexate 15mg or greater without adequate control of RA symptoms • Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease). For more information, please contact Steve Ball at Steven.Ball@umassmed.edu or 508-334-0221.

Do you want help reaching your weight loss goals? (Docket # H00009012)

Participate in a research study that includes a 12-month nutrition and physical activity program. Compensation provided. Interested? Please call (508)856-1534 or e-mail study@umassmed.edu.
**Black Men Needed for Weight Loss App Focus Group (Docket # H00005882)**

Men, we are looking for your feedback on mobile apps and app features to help Blacks/African Americans lose weight and manage stress. Focus group will last 2 hours. You may be eligible if you are black and/or African American, have an interest in losing weight, are over the age of 18, and use a smartphone. Compensation will be provided. Please call Martinus at (508) 856-2209 or e-mail: Martinus.Evans@umassmed.edu.

**Study looking to enroll people who recently lost weight! (Docket # H-00001808)**

“Keeping Weight off” is a NIH-funded research study for people who recently lost weight and want to maintain their weight loss. This study aims to understand the brain changes that accompany participation in weight loss maintenance programs. You may be eligible if you are healthy, 25 to 60 years old, and have lost 5% or more of your weight over the past year without weight-loss surgery. If you decide to participate, you will be enrolled in an 8-week program at UMASS Medical School, Shrewsbury Campus to help you maintain weight loss and will be asked to: undergo a non-invasive MRI and fill out some surveys before and after the course. You will be compensated for your time. Do you think “Keeping Weight Off” is right for you? To complete a brief online pre-screen go to https://arcsapps.umassmed.edu/redcap/surveys/?s=RShqctenyg. Please call Marcela Hayes, Research Coordinator at 508-858-1225 or email keepitoff@umassmed.edu to find out more information.

**The Early Treatment Study (Docket # H-00007426)**

The goal of this study is to compare the standard treatment for psychosis with a treatment version of the medication aripiprazole that is taken only once each month. Study participants at this study location will receive the care your center usually provides. We seek men and women ages 18-35 that have a clinical diagnosis of psychosis and up to 5 years of antipsychotic medication exposure. Those who qualify will receive study-related medical exams, and lab tests at no charge. Compensation for your time and travel is available. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

**The SNP Study (Docket # H-00007610)**

The goal of this 6-week research study is to assess the effectiveness of Sodium Nitroprusside, an FDA approved drug for management of hypertension, can improve symptoms of schizophrenia. We seek men and women ages 18-60 with a diagnosis of schizophrenia. Participants will be compensated for their time and travel, and all information will be kept private. For more information about the study, please call 508-856-MIND (6463) or email MIND@umassmed.edu.

**The Memory Study (Docket # H00004119)**

This study seeks to see if Exenatide, an investigational drug when used in people with schizophrenia, can improve memory and thinking in people with schizophrenia. Participation in the study will last 24 weeks. You will be compensated for your time. For more information about the study, please call us at 508-856-MIND (6463) or email MIND@umassmed.edu.

**The Marijuana Study (Docket # H-00001171)**

The purpose of this 14-week research study is to examine whether FDA approved medication Clozapine can reduce marijuana use in those with schizophrenia. We are looking for people ages 18-55 that have a clinical diagnosis of schizophrenia and use marijuana regularly. Those who qualify will receive study-related medical exams, and lab tests at no charge. Compensation for your time and travel may also be available. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.